Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation

Neuroscience

Volumn 252, Issue , 2013, Pages 118-124

  Federici, M ^a   Latagliata, E C ^a   Rizzo, F R ^a   Ledonne, A ^a   Gu, H H ^b   Romigi, A ^c   Nistico R ^a,d   Puglisi Allegra, S ^a,d   Mercuri, N B ^a,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Amperometry; DAT; Dopamine overflow; Locomotor activation; Modafinil

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; MODAFINIL;

AMPEROMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN ELECTROPHYSIOLOGY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; EVOKED CORTICAL RESPONSE; GENETICALLY ENGINEERED MOUSE STRAIN; IN VITRO STUDY; LOCOMOTION; MOUSE; NERVE CELL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; WILD TYPE;

ACSF; AMPEROMETRY; ARTIFICIAL CEREBROSPINAL FLUID; CONSTANT POTENTIAL AMPEROMETRY; CPA; DAT; DOPAMINE OVERFLOW; DOPAMINE TRANSPORTER; I.P.; INTRAPERITONEALLY; LOCOMOTOR ACTIVATION; MODAFINIL; SNPC; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; BENZHYDRYL COMPOUNDS; BRAIN; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; MICE; MICE, MUTANT STRAINS; MOTOR ACTIVITY; PATCH-CLAMP TECHNIQUES; WAKEFULNESS-PROMOTING AGENTS;

EID: 84883514672     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.07.071     Document Type: Article

References (52)

1. Akaoka H., Roussel B., Lin J.S., Chouvet G., Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 1991, 123:20-22.
2. Armogida M., Giustizieri M., Zona C., Piccirilli S., Nisticò R., Mercuri N.B. N-ethyl lidocaine (QX-314) protects striatal neurons against ischemia: an in vitro electrophysiological study. Synapse 2010, 64:161-168.
3. Ballon J.S., Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006, 67:554-566.
4. Benoit-Marand M., Jaber M., Gonon F. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences. Eur J Neurosci 2000, 12:2985-2992.
5. Besset A., Chetrit M., Carlander B., Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996, 26:60-66.
6. Bonci A., Bernardi G., Grillner P., Mercuri N.B. The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction?. Trends Pharmacol Sci 2003, 24:172-177.
7. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
8. Chen R., Han D.D., Gu H.H. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem 2005, 94:352-359.
9. Duteil J., Rambert F.A., Pessonnier J., Hermant J.F., Gombert R., Assous E. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 1990, 180:49-58.
10. Einhorn L.C., Johansen P.A., White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci 1988, 8:100-112.
11. Federici M., Geracitano R., Bernardi G., Mercuri N.B. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biol Psychiatry 2005, 57:361-365.
12. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., Fuxe K. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998, 253:135-138.
13. Ferraro L., Antonelli T., Tanganelli S., O'Connor W.T., Perez D.M., Mendez-Franco J., Rambert F.A., Fuxe K. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999, 20:346-356.
14. Ferraro L., Fuxe K., Tanganelli S., Fernandez M., Rambert F.A., Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000, 39:1974-1983.
15. Ferraro L., Fuxe K., Tanganelli S., Tomasini M.C., Rambert F.A., Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002, 68:107-112.
16. Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997, 8:2883-2887.
17. Gale S.D., Perkel D.J. Properties of dopamine release and uptake in the songbird basal ganglia. J Neurophysiol 2005, 93:1871-1879.
18. Geracitano R., Federici M., Bernardi G., Mercuri N.B. On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons. Ann N Y Acad Sci 2006, 1074:320-329.
19. Geracitano R., Paolucci E., Prisco S., Guatteo E., Zona C., Longone P., Ammassari-Teule M., Bernardi G., Berretta N., Mercuri N.B. Altered long-term corticostriatal synaptic plasticity in transgenic mice overexpressing human CU/ZN superoxide dismutase (GLY(93)→ALA) mutation. Neuroscience 2003, 118:399-408.
20. Gold L.H., Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996, 126:286-292.
21. Grace A.A., Onn S.P. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 1989, 9:3463-3481.
22. Ishizuka T., Murotani T., Yamatodani A. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci Lett 2010, 483:193-196.
23. Jones S.R., Garris P.A., Wightman R.M. Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. J Pharmacol Exp Ther 1995, 274:396-403.
24. Korotkova T.M., Klyuch B.P., Ponomarenko A.A., Lin J.S., Haas H.L., Sergeeva O.A. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007, 52:626-633.
25. Kraft G.H., Bowen J. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005, 65:1995-1997.
26. Lacey M.G., Mercuri N.B., North R.A. Actions of cocaine on rat dopaminergic neurones in vitro. Br J Pharmacol 1990, 99:731-735.
27. Loland C.J., Mereu M., Okunola O.M., Cao J., Prisinzano T.E., Mazier S., Kopajtic T., Shi L., Katz J.L., Tanda G., Newman A.H. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 2012, 72:405-413.
28. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., Fischman A.J. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006, 319:561-569.
29. Mercuri N.B., Bonci A., Calabresi P., Stefani A., Bernardi G. Properties of the hyperpolarization-activated cation current Ih in rat midbrain dopaminergic neurons. Eur J Neurosci 1995, 7:462-469.
30. Mignot E., Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 2005, 28:754-763.
31. Mignot E., Nishino S., Guilleminault C., Dement W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17:436-437.
32. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
33. Morein-Zamir S., Turner D.C., Sahakian B.J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull 2007, 33:1298-1306.
34. Murillo-Rodríguez E., Haro R., Palomero-Rivero M., Millán-Aldaco D., Drucker-Colín R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007, 176:353-357.
35. Napolitano F., Bonito-Oliva A., Federici M., Carta M., Errico F., Magara S., Martella G., Nisticò R., Centonze D., Pisani A., Gu H.H., Mercuri N.B., Usiello A. Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. J Neurosci 2010, 30:11043-11056.
36. Nieves A.V., Lang A.E. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002, 25:111-114.
37. Patel J., Mooslehner K.A., Chan P.M., Emson P.C., Stamford J.A. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J Neurochem 2003, 85:898-910.
38. Paterson N.E., Fedolak A., Olivier B., Hanania T., Ghavami A., Caldarone B. Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 2010, 95:449-456.
39. Schmaal L., Goudriaan A.E., Joos L., Krüse A.M., Dom G., van den Brink W., Veltman D.J. Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biol Psychiatry 2013, 73:789-795.
40. Schmitt K.C., Reith M.E. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 2011, 6:e25790.
41. Spink A.J., Tegelenbosch R.A., Buma M.O., Noldus L.P. The EthoVision video tracking system - a tool for behavioral phenotyping of transgenic mice. Physiol Behav 2001, 73:731-744.
42. Stone E.A., Cotecchia S., Lin Y., Quartermain D. Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity. Synapse 2002, 46:269-270.
43. Stoops W.W., Lile J.A., Fillmore M.T., Glaser P.E., Rush C.R. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 2005, 182:186-193.
44. Swanson J.M., Greenhill L.L., Lopez F.A., Sedillo A., Earl C.Q., Jiang J.G., Biederman J. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006, 67:137-147.
45. Turner D.C., Clark L., Dowson J., Robbins T.W., Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004, 55:1031-1040.
46. Ventura R., Alcaro A., Cabib S., Conversi D., Mandolesi L., Puglisi-Allegra S. Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion. Neuropsychopharmacology 2004, 29:72-80.
47. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301:1148-1154.
48. Wisor J.P., Eriksson K.S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005, 132:1027-1034.
49. Wisor J.P., Nishino S., Sora I., Uhl G.H., Mignot E., Edgar D.M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21:1787-1794.
50. Wuo-Silva R., Fukushiro D.F., Borçoi A.R., Fernandes H.A., Procópio-Souza R., Hollais A.W., Santos R., Ribeiro L.T., Corrêa J.M., Talhati F., Saito L.P., Aramini T.C., Kameda S.R., Bittencourt L.R., Tufik S., Frussa-Filho R. Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol 2011, 16:565-579.
51. Zifko U.A., Rupp M., Schwarz S., Zipko H.T., Maida E.M. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002, 249:983-987.
52. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., Prisinzano T.E., Baumann M.H. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 2009, 329:738-746.